Certara (NASDAQ:CERT) Shares Down 7.1% – Here’s What Happened

Certara, Inc. (NASDAQ:CERT) shares fell 7.1% on Thursday . The stock traded as low as $11.03 and last traded at $11.31. 243,047 shares traded hands during mid-day trading, a decline of 82% from the average session volume of 1,364,727 shares. The stock had previously closed at $12.18.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CERT. William Blair reaffirmed a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a research report on Tuesday, May 6th. KeyCorp boosted their price objective on shares of Certara from $15.00 to $18.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. Stephens reiterated an “overweight” rating and set a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Finally, Robert W. Baird boosted their price objective on shares of Certara from $9.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, April 11th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $15.67.

Certara Price Performance

The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -55.05, a price-to-earnings-growth ratio of 9.29 and a beta of 1.44. The stock’s 50 day simple moving average is $12.22 and its 200-day simple moving average is $11.87.

Certara (NASDAQ:CERT) last released its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.10 by $0.04. The business had revenue of $106.00 million for the quarter, compared to the consensus estimate of $104.44 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.10 EPS. Equities research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Institutional Trading of Certara

A number of hedge funds have recently added to or reduced their stakes in CERT. Versant Capital Management Inc lifted its holdings in Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock valued at $27,000 after purchasing an additional 1,866 shares in the last quarter. Venturi Wealth Management LLC lifted its holdings in Certara by 839.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after purchasing an additional 2,509 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in Certara during the first quarter valued at $31,000. Wells Fargo & Company MN lifted its holdings in Certara by 48.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after purchasing an additional 1,047 shares in the last quarter. Finally, AlphaQuest LLC purchased a new position in Certara during the first quarter valued at $39,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.